The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2016

Filed:

Oct. 09, 2015
Applicant:

King's College London, London, GB;

Inventors:

Jonathan Patrick Thomas Corcoran, London, GB;

Sarkis Barret Kalindjian, London, GB;

Alan David Borthwick, London, GB;

David Reginald Adams, High Wycombe, GB;

Jane Theresa Brown, Nottingham, GB;

David Michel Adrien Taddei, Nottingham, GB;

Jason John Shiers, Nottingham, GB;

Assignee:

King's College London, London, GB;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/16 (2006.01); C07C 235/84 (2006.01); C07C 233/75 (2006.01); C07C 235/56 (2006.01); C07C 237/42 (2006.01); C07D 213/30 (2006.01); C07D 213/80 (2006.01); C07D 213/81 (2006.01); C07D 237/24 (2006.01);
U.S. Cl.
CPC ...
C07C 235/84 (2013.01); C07C 233/75 (2013.01); C07C 235/56 (2013.01); C07C 237/42 (2013.01); C07D 213/30 (2013.01); C07D 213/80 (2013.01); C07D 213/81 (2013.01); C07D 237/24 (2013.01); C07C 2101/02 (2013.01); C07C 2101/04 (2013.01); C07C 2101/08 (2013.01); C07C 2101/14 (2013.01);
Abstract

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as 'AAA compounds'), which, inter alia, are (selective) retinoic acid receptor α (RARα) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARα, and in the treatment of diseases and conditions that are mediated by RARα, that are ameliorated by the activation of RARα, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.


Find Patent Forward Citations

Loading…